Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Modified creatine greatly increases the performance of skeletal and smooth muscles

A. Soloviev, V. Kozlovsky, D. Nozdrenko, V. Sydorenko, I. Monchak, N. Vdovenko, O. Maidaniuk, V. Fetyukhin

. 2025 ; 41 (-) : 101934. [pub] 20250128

Status not-indexed Language English Country Netherlands

Document type Journal Article

Creatine is a nitrogen-containing carboxylic acid and a main component of phosphocreatine. In recent years, creatine is considered as a component of dietary nutrition, to improve the efficiency of physical activity and increase muscle mass of athletes and older people. Creatine has been shown to be able restore cardiac contractility impairment after myocardial infarction. However, as muscle cells do not synthesise creatine, the efficiency of creatine depends on its transmembrane transport. In our study, we evaluated the effect of «ProCreatine» (ProCr), a novel membrane transporter-independent creatine modification on fatigability of the rat gastrocnemius muscle and portal vein smooth muscle using fatigue stimulation pools. Mechanokinetic and biomechanical markers of fatigue in muscles to maintain the level of isometric tension induced by field electrical stimulation were examined. The results indicate that administration of ProCr to skeletal muscle significantly increases maximal force output, integrated muscle contractile force and significantly increases muscle productivity. We observed positive changes in all studied biochemical indices of fatigue. In addition, ProCr increases the duration of sustaining a constant level of isometric contraction in portal vein smooth muscle caused by electrical stimulation by 6 fold. Regular creatine in the same dose had no significant effect on these parameters neither in skeletal nor in smooth muscles. The data obtained suggest the possibility of using ProCr as a therapeutic agent capable of reducing and correcting pathological conditions of the muscular system that arise during the processes of fatigue in skeletal muscles and smooth muscles of hollow organs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008318
003      
CZ-PrNML
005      
20250422095750.0
007      
ta
008      
250408e20250128ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbrep.2025.101934 $2 doi
035    __
$a (PubMed)39944466
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Soloviev, Anatoly $u Department for Pharmacology of Cellular Signal Systems and Experimental Therapeutics, Institute of Pharmacology and Toxicology, National Academy of Medical Sciences of Ukraine, Kyiv, 03057, Ukraine
245    10
$a Modified creatine greatly increases the performance of skeletal and smooth muscles / $c A. Soloviev, V. Kozlovsky, D. Nozdrenko, V. Sydorenko, I. Monchak, N. Vdovenko, O. Maidaniuk, V. Fetyukhin
520    9_
$a Creatine is a nitrogen-containing carboxylic acid and a main component of phosphocreatine. In recent years, creatine is considered as a component of dietary nutrition, to improve the efficiency of physical activity and increase muscle mass of athletes and older people. Creatine has been shown to be able restore cardiac contractility impairment after myocardial infarction. However, as muscle cells do not synthesise creatine, the efficiency of creatine depends on its transmembrane transport. In our study, we evaluated the effect of «ProCreatine» (ProCr), a novel membrane transporter-independent creatine modification on fatigability of the rat gastrocnemius muscle and portal vein smooth muscle using fatigue stimulation pools. Mechanokinetic and biomechanical markers of fatigue in muscles to maintain the level of isometric tension induced by field electrical stimulation were examined. The results indicate that administration of ProCr to skeletal muscle significantly increases maximal force output, integrated muscle contractile force and significantly increases muscle productivity. We observed positive changes in all studied biochemical indices of fatigue. In addition, ProCr increases the duration of sustaining a constant level of isometric contraction in portal vein smooth muscle caused by electrical stimulation by 6 fold. Regular creatine in the same dose had no significant effect on these parameters neither in skeletal nor in smooth muscles. The data obtained suggest the possibility of using ProCr as a therapeutic agent capable of reducing and correcting pathological conditions of the muscular system that arise during the processes of fatigue in skeletal muscles and smooth muscles of hollow organs.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kozlovsky, Vadym $u LLC "MEDIVALEX", Prague, 15200, Czech Republic
700    1_
$a Nozdrenko, Dmytro $u ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, 03127, Ukraine
700    1_
$a Sydorenko, Vadym $u Department for Pharmacology of Cellular Signal Systems and Experimental Therapeutics, Institute of Pharmacology and Toxicology, National Academy of Medical Sciences of Ukraine, Kyiv, 03057, Ukraine
700    1_
$a Monchak, Igor $u Department for Pharmacology of Cellular Signal Systems and Experimental Therapeutics, Institute of Pharmacology and Toxicology, National Academy of Medical Sciences of Ukraine, Kyiv, 03057, Ukraine
700    1_
$a Vdovenko, Natalia $u Department of Medical and Biological Disciplines, State Scientific Research Institute of Physical Culture and Sports, 03131, Kyiv, Ukraine
700    1_
$a Maidaniuk, Olena $u Department of Medical and Biological Disciplines, State Scientific Research Institute of Physical Culture and Sports, 03131, Kyiv, Ukraine
700    1_
$a Fetyukhin, Volodymyr $u I.F. Lab, LLC, Life Chemicals Inc. Distributor, Kyiv, 02094, Ukraine
773    0_
$w MED00205982 $t Biochemistry and biophysics reports $x 2405-5808 $g Roč. 41 (20250128), s. 101934
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39944466 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095751 $b ABA008
999    __
$a ok $b bmc $g 2306335 $s 1245393
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 41 $c - $d 101934 $e 20250128 $i 2405-5808 $m Biochemistry and biophysics reports $n Biochem Biophys Rep $x MED00205982
LZP    __
$a Pubmed-20250408

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...